Filtered By:
Drug: Zivast

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 857 results found since Jan 2013.

Statin therapy in acute ischemic stroke: Time for large randomized trials?
Despite improvements in stroke mortality coupled with therapeutic advances, stroke patients often face the prospect of substantial disability. Novel strategies are clearly needed to further improve stroke outcomes. These might include new indications for previously licensed drugs proven effective and safe in related disease processes,1 such as statins. Unlike strong evidence supporting statin use in cardiovascular risk reduction and acute myocardial ischemia, their effects on cerebral tissue and potential benefits on stroke outcomes remain poorly understood and understudied. The only current stroke-specific indication for ...
Source: Neurology - March 21, 2016 Category: Neurology Authors: Charidimou, A., Merwick, A. Tags: All Cerebrovascular disease/Stroke, Infarction EDITORIALS Source Type: research

Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke: A Randomized Trial
Abstract: Statins have beneficial effects on cerebral circulation and brain parenchyma during ischemic stroke and reperfusion. The primary hypothesis of this randomized parallel trial was that treatment with 80 mg/day of atorvastatin administered early at admission after acute atherosclerotic ischemic stroke could reduce serum levels of markers of immune-inflammatory activation of the acute phase and that this immune-inflammatory modulation could have a possible effect on prognosis of ischemic stroke evaluated by some outcome indicators. We enrolled 42 patients with acute ischemic stroke classified as large arteries ath...
Source: Medicine - March 1, 2016 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Atorvastatin inhibits miR-143 expression: A protective mechanism against oxidative stress in cardiomyocytes
Statins are unequivocally the most widely prescribed drug for the primary and secondary prevention of coronary artery disease worldwide [1]. Atorvastatin is the most commonly prescribed statin drug due to its lower therapeutic dose comared to others. The well-tolerated and high benefit–risk ration of atorvastain has been demonstrated in clinical trials [2]. Atorvastatin reduce the risk of myocardial infarction, stroke, and death, primarily inhibiting reactive oxygen species (ROS) [3].
Source: International Journal of Cardiology - March 1, 2016 Category: Cardiology Authors: Shanshan Tian, Wei Zhao, Di Yang, Yang Yu, Jiaqi Zou, Zhiyan Liu, Zhimin Du Tags: Correspondence Source Type: research

Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or transient ischaemic attack.
CONCLUSIONS: Compared with atorvastatin 80 mg, atorvastatin 40 mg plus ezetimibe 10 mg increases the likelihood of achieving LDLc goals after ischaemic stroke or transient ischaemic attack. Both treatments were safe and well tolerated. PMID: 26916323 [PubMed - in process]
Source: Revista de Neurologia - February 27, 2016 Category: Neurology Authors: Palacio E, Viadero-Cervera R, Revilla M, Larrosa-Campo D, Acha-Salazar O, Novo-Robledo F, Oterino A Tags: Rev Neurol Source Type: research

Benefit-risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment
Conclusions The results of benefit–risk assessment from every perspective were somewhat consistent. This study demonstrated the feasibility of applying a discrete choice experiment in the benefit–risk assessment of drugs and encouraged the engagement of multiple stakeholders in the decision-making process.
Source: BMJ Open - February 25, 2016 Category: Journals (General) Authors: Wanishayakorn, T., Sornlertlumvanich, K., Ngorsuraches, S. Tags: Open access, Cardiovascular medicine, Health policy Research Source Type: research

Atorvastatin treatment is associated with increased BDNF level and improved functional recovery after atherothrombotic stroke
.
Source: International Journal of Neuroscience - February 21, 2016 Category: Neuroscience Authors: Jingmiao Zhang Xiali Mu Dane A Breker Ying Li Zongliang Gao Yonglu Huang Source Type: research

Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis
The 4D (Die Deutsche Diabetes Dialyse) Study was a randomized, double-blind trial comparing 4 years of treatment with atorvastatin to placebo in 1255 hemodialysis patients with type 2 diabetes. The primary end point of cardiovascular events (cardiac death, myocardial infarction, and stroke) was non-significantly reduced by 8%. However, long-term effects remained uncertain. Therefore, surviving patients were invited to a follow-up survey done by questionnaire. Post-trial statin therapy was at nephrologist discretion, and outcomes were centrally adjudicated and analyzed by intention to treat and time to first event in the or...
Source: Kidney International - February 17, 2016 Category: Urology & Nephrology Authors: Vera Krane, Kay-Renke Schmidt, Lena J. Gutjahr-Lengsfeld, Johannes F.E. Mann, Winfried März, Florian Swoboda, Christoph Wanner, 4D Study Investigators (the German Diabetes and Dialysis Study Investigators) Tags: Clinical Trial Source Type: research

Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease
Abstract After careful review of randomized cardiovascular outcomes trial data, the 2013 ACC/AHA cholesterol guideline focused on using the appropriate intensity of statin therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk and moved away from recommending specific low-density lipoprotein cholesterol (LDL-C) treatment targets. In patients who have had a stroke or other clinical ASCVD event, a high-intensity statin should be initiated up to age 75 years unless there are safety concerns, including a history of hemorrhagic stroke. A moderate-intensity statin is recommended if there are safety conc...
Source: Current Neurology and Neuroscience Reports - February 2, 2016 Category: Neuroscience Source Type: research

Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (From the Treating to New Targets TNT Study)
Statins may have nephroprotective as well as cardioprotective effects in patients with cardiovascular disease. In the Treating to New Targets (TNT) study (NCT00327691), patients with coronary heart disease (CHD) were randomized to atorvastatin 10- or 80-mg/day and followed for 4.9 years. The relationship between intra-study change in estimated glomerular filtration rate (eGFR) from baseline and the risk of major cardiovascular events (MCVE, defined as CHD death, nonfatal non-procedure-related myocardial infarction, resuscitated cardiac arrest or fatal or nonfatal stroke) was assessed among 9500 patients stratified by renal...
Source: The American Journal of Cardiology - January 28, 2016 Category: Cardiology Authors: James Shepherd, Andrei Breazna, Prakash C. Deedwania, John C. LaRosa, Nanette K. Wenger, Michael Messig, Daniel J. Wilson, Treating to New Targets Steering Committee and Investigators Source Type: research

Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study
In this study, 5857 patients received coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. There were no differences in comorbidity or use of antihypertensive drugs between patients who received CYP3A4-metabolized statins and those who received non-CYP3A4-metabolized statins. Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury (adjusted odds ratio [OR] = 2.12; 95% CI = 1.35–3.35), hyperkalemia (adjusted OR = 2.94; 95% CI = 1.36–6.35), acute myocardial infarction (adjusted OR = 1.55; 95% CI = 1.16–2.07), and acute ischemic ...
Source: Medicine - January 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Cortical hemiballism: A case of hemiballismus associated with parietal lobe infarct
Conclusion: Lesions affecting various areas outside the STN can cause hemiballism and usually carries a good prognosis with spontaneous resolution. Acute thrombolytic therapy may be considered on an individual basis. Treatment with antipsychotics can be useful for severe and recurring symptoms.
Source: North American Journal of Medical Sciences - December 30, 2015 Category: Journals (General) Authors: Pragya ShresthaJanak AdhikariDilli PoudelRanjan PathakParas Karmacharya Source Type: research

Metabolic syndrome impairs reactivity and wall mechanics of cerebral resistance arteries in obese Zucker rats
This study determined the structural and functional changes in the middle cerebral arteries (MCA) during the progression of MetS and the effects of chronic pharmacological interventions on mitigating vascular alterations in obese Zucker rats (OZR), a translationally relevant model of MetS. The reactivity and wall mechanics of ex vivo pressurized MCA from lean Zucker rats (LZR) and OZR were determined at 7–8, 12–13, and 16–17 wk of age under control conditions and following chronic treatment with pharmacological agents targeting specific systemic pathologies. With increasing age, control OZR demonstrated r...
Source: AJP: Heart and Circulatory Physiology - December 1, 2015 Category: Cardiology Authors: Brooks, S. D., DeVallance, E., d'Audiffret, A. C., Frisbee, S. J., Tabone, L. E., Shrader, C. D., Frisbee, J. C., Chantler, P. D. Tags: CALL FOR PAPERS Source Type: research

Atorvastatin-meloxicam association inhibits neuroinflammation and attenuates the cellular damage in cerebral ischemia by arterial embolism.
CONCLUSION: These results suggest that the meloxicam-atorvastatin association attenuates astrocytic and microglial response in the inflammatory process after cerebral ischemia by arterial embolism, reducing neurodegeneration and restoring the morphological and functional balance of nervous tissue . PMID: 25504124 [PubMed - indexed for MEDLINE]
Source: Biomedica : Revista del Instituto Nacional de Salud - November 28, 2015 Category: Global & Universal Tags: Biomedica Source Type: research

Effect of atorvastatin co‐treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke
Source: International Journal of Stroke - November 18, 2015 Category: Neurology Authors: Atsushi Mizuma, Kazuyuki Iijima, Saori Kohara, Mie Shimizu, Ryoko Imazeki, Tsuyoshi Uesugi, Yoichi Ohnuki, Shunya Takizawa Tags: Letter to the editor Source Type: research